Zelboraf Tripped Up By Cost At NICE; Can Better Survival Estimates Save It?
This article was originally published in The Pink Sheet Daily
Despite being convinced of its clinical effectiveness, NICE demands more data on Roche’s melanoma drug Zelboraf to prove its cost-effectiveness.
You may also be interested in...
NICE has recommended Roche’s Zelboraf and BMS’ Yervoy, as expected based partly on undeniable life extension capabilities, but also on secret price discounts offered by both manufacturers.
Roche’s Zelboraf and Bristol-Myers Squibb’s Yervoy exceed NICE’s cost-effectiveness limit, but are still waved through as targeting unmet medical need.
Supported by robust data demonstrating knock-out response rates, Roche/Genentech’s Zelboraf (vemurafenib) has sailed through the FDA approval process, aided by a push from the agency.